Although the technological advances in CSF biomarkers (Aβ or tau) and imaging examinations (Aβ/tau PET) and increased attention paid to the care of these participants, to some extent, have improved the diagnosis of dementia and increased their quality of life, there is no effective treatment or drugs in those who already have the clinical symptoms of cognitive impairment. The gene discussed is MAPT; the disease is dementia.